FDA Label Expansion of Zepbound and Market Expansion

Eli Lilly and Company (LLY)'s dual GIP/GLP-1 receptor agonist, Zepbound (tirzepatide), received FDA approval on December 20, 2024, for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. This approval is strategically significant as it positions Lilly in a high-unmet medical need area—sleep disorders—competing with Novo Nordisk's Wegovy (semaglutide), which has demonstrated cardiovascular benefits. By moving beyond weight loss to directly addressing obesity-related complications, Zepbound is now recognized as a medical tool with the potential to strengthen Lilly's market dominance.

Clinical Efficacy Proven by Phase 3 Data

The FDA approval was based on the results of the Phase 3 SURMOUNT-OSA (NCT05412004) trial, which involved 469 patients with obesity and OSA. Patients receiving weekly tirzepatide showed a dramatic improvement in apnea-hypopnea index (AHI), a key indicator of sleep-related breathing disorders, with an average reduction of 25–29 events per hour. Notably, approximately 50% of patients achieved resolution or asymptomatic levels of OSA after one year of treatment. This breakthrough demonstrates that medication alone can significantly improve respiratory function, potentially replacing the inconvenience of positive airway pressure (PAP) therapy.

Explosive Sales Growth and Future Market Outlook

Since its initial approval as an obesity treatment in November 2023, Zepbound has recorded explosive growth, shaking up the market. Global sales of Zepbound surged from $4.9 billion (approximately 65 billion USD) in 2024 to $13.5 billion (approximately 180 billion USD) in 2025, a 175% increase, solidifying its position as a blockbuster drug. Goldman Sachs estimates the global obesity treatment market will reach $100 billion by 2030, while Morgan Stanley forecasts it could reach up to $150 billion by 2035. This new indication is expected to significantly expand insurance coverage and further accelerate sales growth.

Competitive Landscape Shift and Impact on the Global Pharma Industry

The obesity treatment market is currently dominated by a fierce rivalry between Eli Lilly's tirzepatide and Novo Nordisk's semaglutide. While Novo Nordisk has emphasized cardiovascular risk reduction with Wegovy to capture market share, Lilly has secured a differentiated clinical value by proactively obtaining OSA approval. This expansion of indications is expected to extend into other comorbid areas such as non-alcoholic steatohepatitis (NASH/MASH) and Alzheimer's disease. For investors, this marks a clear milestone showing that obesity treatments are transitioning from cosmetic purposes to essential pharmaceuticals.